Management of metastatic castration-resistant prostate cancer after first-line docetaxel

Harrington, J.A. and Jones, R.J. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer, 47(14), pp. 2133-2142. (doi:10.1016/j.ejca.2011.04.036)

Full text not currently available from Enlighten.

Abstract

Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Harrington, J.A., and Jones, R.J.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:European Journal of Cancer
ISSN:0014-2964
Published Online:10 June 2011

University Staff: Request a correction | Enlighten Editors: Update this record